Meeting
2019 ASCO Annual Meeting
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.
Authors
Patrick Schoffski
UZ Leuven, Leuven, Belgium
Patrick Schoffski , Philippe Georges Aftimos , Christophe Massard , Antoine Italiano , Christiane Jungels , Karen Andreas , Mitchell Keegan , Peter T.C. Ho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT03780517
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS3162)
DOI
10.1200/JCO.2019.37.15_suppl.TPS3162
Abstract #
TPS3162
Poster Bd #
146a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.
First Author: Caicun Zhou
Poster
2016 ASCO Annual Meeting
Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors.
First Author: Tina Cascone
Poster
2024 ASCO Annual Meeting
A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.
First Author: Elena Garralda
Poster
2022 ASCO Annual Meeting
A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).
First Author: Nathan A. Pennell